Business
Arecor Granted Patents in India and the US
Arecor Granted Patents in India and the US.
About this update from Arecor Therapeutics Plc
[{"type":"text","content":"\n \n \n \n Arecor Therapeutics plc\n \n \n \n (\"Arecor\" or the \"Group\")\n \n \n \n \n \n ARECOR GRANTED PATENTS IN INDIA AND THE UNITED STATES PROTECTING PROPRIETARY FORMULATIONS OF DIFFERENTIATED BIOPHARMACEUTICAL PRODUCTS\n \n \n \n \n \n - Patents further strengthen Group's extensive patent portfolio protecting its proprietary diabetes portfolio and demonstrate potential of innovative\n \n Arestat™ technologyin development of enhanced formulations of high value biologics\n \n \n \n \n \n \n \n Cambridge, UK, 16 February 2023:\n \n Arecor Therapeutics plc (AIM: AREC), the biopharmaceutical group advancing today's therapies to enable healthier lives,\n is pleased to announce that the Indian Patent Office has granted a patent (IN412485) protecting novel formulations of the Group's proprietary insulin products, AT247 and AT278, until 2038. In addition, the United States Patent and Trademark Office has granted two patents (\n US11534402 and US11534403) protecting the Group's novel formulations of high-concentration adalimumab until 2038.\n \n \n \n \n \n Dr Jan Jezek, Chief Scientific Officer at Arecor, commented:\n \"As we continue to successfully apply our Arestat™ technology to develop enhanced pharmaceutical products, it is crucial that we maintain strong IP protection, both for the fundamental features of our technology and for the final drug products. These three recently granted patents demonstrate the continued strength of Arecor's IP portfolio, providing further protection for our differentiated in-house development products AT247 and AT278, as well as within competitive IP areas such as that surrounding adalimumab formulations. These patents further reinforce the strength of Arecor's technology and expertise in valuable commercial areas such as inflammatory diseases and diabetes.\"\n \n \n \n \n \n The patent granted in India protects the formulations of Arecor's clinical insulin candidates, AT247 and AT278, that have been designed to significantly ac\n celerate insulin absorption post injection across a range of insulin concentrations and thus enable more effective management of blood glucose levels for people living with diabetes,\n particularly around difficult to manage mealtimes. The granted Indian patent is an important milestone in\n Arecor's strategy to generate a strong ...